NxStage (NXTM) Receives Consensus Rating of “Hold” from Brokerages
NxStage (NASDAQ:NXTM) has been given an average recommendation of “Hold” by the eleven research firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation and nine have issued a hold recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $30.00.
Several research firms have recently weighed in on NXTM. ValuEngine lowered shares of NxStage from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. BidaskClub raised shares of NxStage from a “strong sell” rating to a “sell” rating in a report on Monday, February 5th. Finally, Zacks Investment Research raised shares of NxStage from a “sell” rating to a “hold” rating in a report on Friday, January 26th.
Shares of NASDAQ:NXTM traded up $0.15 during trading on Thursday, hitting $25.95. 18,946 shares of the stock traded hands, compared to its average volume of 568,234. The firm has a market cap of $1,709.08, a price-to-earnings ratio of -368.57 and a beta of -0.02. NxStage has a 52-week low of $20.45 and a 52-week high of $30.80.
A number of hedge funds and other institutional investors have recently modified their holdings of NXTM. Public Employees Retirement Association of Colorado purchased a new stake in NxStage in the 4th quarter worth $128,000. Prudential Financial Inc. purchased a new stake in NxStage in the 3rd quarter worth $202,000. Guggenheim Capital LLC increased its holdings in NxStage by 35.5% in the 4th quarter. Guggenheim Capital LLC now owns 11,247 shares of the medical device company’s stock worth $273,000 after acquiring an additional 2,949 shares in the last quarter. FNY Partners Fund LP purchased a new stake in NxStage in the 4th quarter worth $300,000. Finally, Teacher Retirement System of Texas purchased a new stake in NxStage in the 4th quarter worth $549,000. 84.14% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “NxStage (NXTM) Receives Consensus Rating of “Hold” from Brokerages” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/04/17/nxstage-nxtm-receives-consensus-rating-of-hold-from-brokerages.html.
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Receive News & Ratings for NxStage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage and related companies with MarketBeat.com's FREE daily email newsletter.